NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Quantum BioPharma Ltd. QNTM
5 fiscal years on record · USD · FY2022 reported
SEC FILINGS ONLY
EPS · FY22
$-0.69
Dividend / sh · FY22
—
Payout · FY22
—
ROE · FY22
-77.3%
Net margin · FY22
—
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
—
Revenue, FY2022 · full 5-year series below
Revenue
Net income
Per share
USD -0.69
Diluted EPS, FY2022
EPS
The company pays no cash dividend.
Profitability
-77.3%
Return on equity, FY2022
ROE
Operating margin—
Net margin—
Return on assets-46.6%
Each USD of equity lost 77 cents this year.
Returned to shareholders
—
returned in FY2022 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where the series crosses a loss.
Share base
—
Shares outstanding, FY2022
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 38.4M
total assets, end of FY2022
Total assetsUSD 38.4M
EquityUSD 30.5M
CashUSD 17.0M
Current ratio2.28×
Equity funds 80% of total assets.
History
5 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2022
2021
2020
2019
2018
Revenue $B
·
·
·
0.0
·
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.0
−0.0
−0.0
−0.0
−0.0
Income tax $B
·
·
·
·
·
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−0.69
−0.97
−2.36
·
·
Dividend / sh $
·
·
·
·
·
Payout %
·
·
·
·
·
ROE %
−77.3
·
·
·
·
Shares out B
·
·
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
16 of 20
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 1 failures and 3 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed